Zobrazeno 1 - 10
of 1 381
pro vyhledávání: '"Halks-Miller M"'
Autor:
Alexander GE; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America., Lin W; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America., Ortega FE; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America., Ramaiah M; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America., Jung B; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America., Ji L; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America., Revenkova E; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America., Shah P; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America., Croisetiere C; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America., Berman JR; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America., Eubank L; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America., Naik G; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America., Brooks J; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America., Mich A; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America., Shojaee S; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America., Ronaghi N; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America., Chawla H; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America., Hou X; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America., Liu Q; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America., Yakym CAV; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America., Moradi PW; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America., Halks-Miller M; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America., Aravanis AM; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America., Parpart-Li S; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America., Hunkapiller N; GRAIL, LLC, A Subsidiary of Illumina, Inc., Currently Held Separate from Illumina, Inc., Under the Terms of the Interim Measures Order of the European Commission Dated 29 October 2021, Menlo Park, California, United States of America.
Publikováno v:
PloS one [PLoS One] 2023 Apr 14; Vol. 18 (4), pp. e0283001. Date of Electronic Publication: 2023 Apr 14 (Print Publication: 2023).
Autor:
Son, So-Eun1 (AUTHOR) seson@khu.ac.kr, Im, Dong-Soon1,2 (AUTHOR) imds@khu.ac.kr
Publikováno v:
International Journal of Molecular Sciences. Sep2024, Vol. 25 Issue 17, p9532. 16p.
Autor:
Ko, Randy F.1 (AUTHOR), Davidson, Oliver Q. C.2 (AUTHOR), Ahmed, Michael A.2 (AUTHOR), Clark, Ross M.3,4 (AUTHOR), Brandenburg, Jacquelyn S.3 (AUTHOR), Pankratz, Vernon S.5 (AUTHOR), Sharma, Geetanjali1 (AUTHOR), Hathaway, Helen J.4,6 (AUTHOR), Prossnitz, Eric R.1,6,7 (AUTHOR) eprossnitz@salud.unm.edu, Howdieshell, Thomas R.2 (AUTHOR) thowdieshell@augusta.edu
Publikováno v:
Scientific Reports. 8/8/2024, Vol. 14 Issue 1, p1-12. 12p.
Autor:
H S Qian, Katalin Kauser, Huw Ly, Cashion L, Liu P, Halks-Miller M, Dole Wp, Jun Yu, Hill Sm, Jin F, Blasko E, Richard N. Harkins, Vergona R, Peter J. Kretschmer, Gabor M. Rubanyi, P Szymanski, William C. Sessa, A Orme
Publikováno v:
Gene Therapy. 13:1342-1350
Gene delivery of angiogenic growth factors is a promising approach for the treatment of ischemic cardiovascular diseases. However, success of this new therapeutic principle is hindered by the lack of critical understanding as to how disease pathology
Autor:
Grubić Kezele, Tanja1,2 (AUTHOR) tanja.grubic@uniri.hr, Omrčen, Hrvoje3 (AUTHOR) hrvoje.omrcen@zzjzpgz.hr, Batičić, Lara4 (AUTHOR) lara.baticic@uniri.hr, Šućurović, Sandra5 (AUTHOR) sandra.sucurovic@kclj.si, Zoričić Cvek, Sanja6 (AUTHOR) sanja.zoricic@uniri.hr
Publikováno v:
International Journal of Molecular Sciences. Jul2024, Vol. 25 Issue 14, p7864. 16p.
Autor:
Snipes, Madeline1 (AUTHOR), Stokes, Stephanie1 (AUTHOR), Vidalin, Amy1 (AUTHOR), Moore, Lee D.2 (AUTHOR), Schlabritz-Lutsevich, Natalia3 (AUTHOR), Maher, James1 (AUTHOR) jamaher@augusta.edu, Das, Sofia Priyadarsani (AUTHOR)
Publikováno v:
Case Reports in Genetics. 7/16/2024, Vol. 2024, p1-5. 5p.
Publikováno v:
Journal of International Reproductive Health/Family Planning. Jul2024, Vol. 43 Issue 4, p279-283. 5p.
Autor:
Di Gregoli, Karina1 (AUTHOR) karina.digregoli@gmail.com, Atkinson, Georgia1 (AUTHOR), Williams, Helen1 (AUTHOR), George, Sarah J.1 (AUTHOR), Johnson, Jason L.1 (AUTHOR) jason.l.johnson@bristol.ac.uk
Publikováno v:
International Journal of Molecular Sciences. Jun2024, Vol. 25 Issue 11, p5809. 18p.
Autor:
Newland, Verayna1 vspell@iu.edu, Jantzie, Lauren L.2,3 jantzie@jhmi.edu, Blazer-Yost, Bonnie L.1 bblazer@iu.edu
Publikováno v:
Physiologia. Jun2024, Vol. 4 Issue 2, p182-201. 20p.
Autor:
Liang, Dong1 (AUTHOR), Lin, Ying1 (AUTHOR), Luo, Chunyu1 (AUTHOR), Li, Hang1 (AUTHOR), Hu, Ping1 (AUTHOR) njfybjyhuping@163.com, Xu, Zhengfeng1 (AUTHOR) zhengfeng_xu_nj@163.com
Publikováno v:
Molecular Genetics & Genomic Medicine. Jun2024, Vol. 12 Issue 6, p1-7. 7p.